Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting

10 Nov 2022
www.biospace.com
CollaborateSmall molecular drugImmunotherapy
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics Limited (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted immune cell agonist (Bicycle TICA), and BT7455, an EphA2/CD137 Bicycle TICA, will be presented in five poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, being held in Boston, M.A. and virtually on November 8-12, 2022. Details on Bicycle’s poster presentations at SITC are as follows: Poster Title: NKp46 engaging Bicycle NK-TICA® drives tumor targeted cytotoxicity Presenter: Alexandra Rezvaya, Bicycle Therapeutics Session Title: Immuno-conjugates and chimeric molecules Poster #: 1207 Date and Time: Thursday, November 10 at 9 a.m. ET Poster Title: Utility of humanized animal models for in vivo evaluation of NK-TICA®, novel Bicycle tumor-targeted immune cell agonist® (Bicycle TICA®) designed to engage NK cells Presenter: Lukas Stanczuk, Bicycle Therapeutics Session Title: Novel single-agent immunotherapies Poster #: 1388 Date and Time: Friday, November 11 at 9 a.m. ET Poster Title: Transcriptional profiling of Bicycle® tumor-targeted CD137 agonist-treated mouse tumors revealed an early and rapid activation of myeloid cells followed by infiltration of cytotoxic T cells into the tumor Presenter: Johanna Lahdenranta, Bicycle Therapeutics Session Title: Novel single-agent immunotherapies Poster #: 1356 Date and Time: Friday, November 11 at 9 a.m. ET Poster Title: BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist®, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy Presenters: Kristin Hurov and Lia Luus, Bicycle Therapeutics Session Title: Novel single-agent immunotherapies Poster #: 1340 Date and Time: Friday, November 11 at 9 a.m. ET Poster Title: In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems for industry Presenter: Anna Licht, Bicycle Therapeutics Session Title: Immune cell types and biology Poster #: 980 Date and Time: Friday, November 11 at 9 a.m. ET The poster presentations are available on the Publications section of bicycletherapeutics.com. About Bicycle Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC®) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.